Burning Rock Biotech Limited (BNR)
NASDAQ: BNR · Real-Time Price · USD
9.32
-0.78 (-7.72%)
At close: May 29, 2026, 4:00 PM EDT
9.95
+0.63 (6.76%)
After-hours: May 29, 2026, 7:08 PM EDT
Burning Rock Biotech Revenue
In the year 2025, Burning Rock Biotech had annual revenue of 539.57M CNY with 4.60% growth. Burning Rock Biotech had revenue of 126.32M in the quarter ending December 31, 2025, with 0.23% growth.
Revenue (ttm)
539.57M CNY
Revenue Growth
+4.60%
P/S Ratio
1.27
Revenue / Employee
808,948 CNY
Employees
667
Market Cap
98.29M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 539.57M | 23.75M | 4.60% |
| Dec 31, 2024 | 515.82M | -21.61M | -4.02% |
| Dec 31, 2023 | 537.44M | -25.80M | -4.58% |
| Dec 31, 2022 | 563.24M | 55.38M | 10.90% |
| Dec 31, 2021 | 507.86M | 77.96M | 18.13% |
| Dec 31, 2020 | 429.90M | 48.23M | 12.64% |
| Dec 31, 2019 | 381.68M | 172.81M | 82.74% |
| Dec 31, 2018 | 208.87M | 97.70M | 87.89% |
| Dec 31, 2017 | 111.17M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
| MDxHealth | 110.97M |
| FONAR | 105.34M |
| Biodesix | 96.10M |
| Prenetics Global | 92.39M |
| Exagen | 68.38M |
BNR News
- 4 weeks ago - Burning Rock Publishes 2025 Annual Report on Form 20-F - GlobeNewsWire
- 2 months ago - Burning Rock Biotech founder and CEO purchases company ADSs - TheFly
- 2 months ago - Burning Rock Announces Founder's Purchase of Its ADSs - GlobeNewsWire
- 2 months ago - Burning Rock Biotech reports Q4 EPS (RMB0.16) vs. (RMB0.79) last year - TheFly
- 2 months ago - Burning Rock Biotech Annual report: Q4 2025 - Filings
- 2 months ago - Burning Rock Biotech Earnings release: Q4 2025 - Filings
- 2 months ago - Burning Rock Biotech Slides: Q4 2025 - Filings
- 5 months ago - Burning Rock Biotech CEO Yusheng Han purchases $811,721 of ADSs - TheFly